Matthanja Bieze

Dr. Matthanja Bieze

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
MBMatthanja Bieze
Matthanja Bieze
AHAnnelotte Pauline van Haaps
Annelotte Pauline van Haaps
LKLeonardo Kapural
Leonardo Kapural
SLSean Li
Sean Li
KFKris Ferguson
Kris Ferguson
JKJan Willem Kallewaard
Jan Willem Kallewaard
Aim: Visceral pain, characterized by pain that is diffuse and challenging to localize, occurs frequently and is difficult to treat. In cases where the pain becomes intractable despite optimal medical management, it can affect patients’ Quality of Life (QoL). Spinal Cord Stimulation (SCS) has emerged as a potential solution for intractable visceral pain. Purpose: In this narrative review, we collected all evidence regarding the efficacy of SCS for visceral pain across various underlying conditions. Methods: A comprehensive literature search was conducted in PubMed, Embase, and Web of Science in which articles published from October 1st, 1963 up to March 7th, 2023 were identified. Results: Seventy articles were included in this review of which most were retrospective cohort studies, case series and case reports. The studies, often with a small number of participants, reported on SCS for chronic pancreatitis, anorectal pain and bowel disorders, gynaecological diagnoses, visceral pelvic pain, urological disorders and finally general visceral pain. They found positive effects on pain and/or symptom relief, opioid consumption, anxiety and depression and QoL. Complications occurred frequently but were often minor and reversible. Conclusion: Better screening and selection criteria need to be established to optimally evaluate eligible patients who might benefit from SCS. A positive outcome of a sympathetic nerve block appears to be a potential indicator of SCS effectiveness. Additionally, women receiving SCS for endometriosis had a better outcome compared to other indications. Finally, SCS could also relief functional symptoms such as voiding problems and gastroparesis. Complications could often be resolved with revision surgery. Since SCS is expensive and not always covered by standard health insurance, the incorporation of cost-analyses is recommended. In order to establish a comprehensive treatment plan, including selection criteria for SCS, rigorous prospective, possibly randomized and controlled studies that are diagnosis-oriented, with substantial follow-up and adequate sample sizes, are needed.

1 September 2009 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
DMDouwe Johannes Mulder
Douwe Johannes Mulder
MBMatthanja Bieze
Matthanja Bieze
RGR. Graaff
R. Graaff
ASA. J. Smit
A. J. Smit
JHJ. M. M. Hooymans
J. M. M. Hooymans
Background/aims Skin autofluorescence (AF) is a non-invasive marker for advanced glycation endproducts (AGE) in tissues, making use of their characteristic AF pattern. The aim of this study was to investigate whether skin AF is increased in patients with neovascular age-related macular degeneration (AMD) compared with healthy controls. Methods Skin AF was assessed in 73 consecutive patients with active and documented neovascular AMD without evidence for diabetic or hypertensive retinopathy and in 31 healthy age-matched controls. Exclusion criteria were: known renal disease, current inflammatory or malignant disease, or skin type V or VI. Skin AF was measured on the forearm and was calculated as a ratio of mean intensities detected from the skin between 420–600 and 300–420 nm. Student t test and χ2 test were used to compare differences between groups. Results Skin AF was increased in neovascular AMD compared with controls (2.57±0.68 vs 2.23±0.63 arbitrary units × 10−2; p=0.018). In patients without vascular risk factors or cardiovascular disease, skin AF was not significantly higher than that of the controls. Skin AF correlated with age in both patients and controls. Conclusion Skin AF is increased in patients with neovascular AMD, suggesting that AMD is accompanied by enhanced systemic AGE accumulation, which may indicate a role in the pathophysiology of AMD.

13 September 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
IKIsabella Kojundzic
Isabella Kojundzic
NANeeki Alavi
Neeki Alavi
ALAustin Lam
Austin Lam
KKKeyvan Karkouti
Keyvan Karkouti
JCJeannie Callum
Jeannie Callum
JBJustyna Bartoszko
Justyna Bartoszko

16 October 2024 in Brazilian Journal of Anesthesiology (English Edition)
Verified
Journal Article
Open access
MBMatthanja Bieze
Matthanja Bieze
AZAmir Zabida
Amir Zabida
EMEduarda Schutz Martinelli
Eduarda Schutz Martinelli
RCRebecca Caragata
Rebecca Caragata
SWStella Wang
Stella Wang
SMStuart A McCluskey
Stuart A McCluskey
Introduction: Acute Kidney Injury (AKI) following Liver Transplantation (LT) is associated with prolonged ICU and hospital stay, increased risk of chronic renal disease, and decreased graft survival. Intraoperative hypotension is a modifiable risk factor associated with postoperative AKI. We aimed to determine in which phase of LT hypotension has the strongest association with AKI: the anhepatic or neohepatic phase. Methods: This retrospective cohort study included adult patients undergoing LT between January 2010 and June 2022. Exclusion criteria were re-do or combined transplantations, preoperative dialysis, and early graft failure or death. Primary outcome was AKI as defined by KDIGO. Hypotension was Mean Arterial Pressure (MAP) below predefined thresholds in minutes. Risk adjusted logistic regression analysis considered hypotension in 3 periods: the total procedure, anhepatic phase, and neohepatic phase. Results: Our cohort included 1153 patients. The median MELD-NA score was 19 (IQR 11-28), and 412 (35.9%) were living-related donations. AKI occurred in 544 patients (47.2%). The unadjusted model showed an association with AKI for MAP <60 mmHg (OR = 1.011 [1.0, 1.022], p = 0.047) and MAP <55 mmHg (OR = 1.023 [1.002, 1.047], p = 0.040) in the anhepatic phase, and for MAP <60 mmHg (OR = 1.032 [1.01, 1.056], p = 0.006) in the neohepatic phase. The adjusted model did not reach significance in the subgroups but did in the total procedure: MAP < 60 mmHg (OR = 1.005 [1.002, 1.008], p < 0.001) and MAP < 55 mmHg (OR = 1.008 [1.003-1.013], p = 0.004). Conclusion: Intraoperative hypotension is independently associated with AKI following LT. This association is seen during the anhepatic phase. Maintaining MAP above 60 mmHg may improve kidney function after LT.

23 October 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
MBMatthanja Bieze
Matthanja Bieze
RMRyan McGinn
Ryan McGinn
MBMarta Berrio-Valencia
Marta Berrio-Valencia
RTRobert Talarico
Robert Talarico
GMGuillaume Martel
Guillaume Martel
DMDaniel I. McIsaac
Daniel I. McIsaac

3 December 2025 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Open access
AHAnnelotte P. van Haaps
Annelotte P. van Haaps
JKJan Willem Kallewaard
Jan Willem Kallewaard
MBMatthanja Bieze
Matthanja Bieze
MEMicha Erwteman
Micha Erwteman
ANAnnemiek Nap
Annemiek Nap
VMVelja Mijatovic
Velja Mijatovic
Endometriosis, an estrogen-dependent chronic inflammatory disease, can cause visceral pain. Owing to its chronic nature, treatment can be challenging and insufficient in reducing all symptoms despite adequate management. Spinal-cord stimulation (SCS), a well-established treatment, could be used in treating intractable, endometriosis-related visceral pain and thereby improve quality of life (QoL). A prospective, unblinded feasibility study (NCT05558540) was conducted between May 2022 and January 2025. We included patients with endometriosis reporting pain scores ≥ 5 (numeric rating scale [NRS], 0-10) who are experiencing dysmenorrhea, dyspareunia, and/or chronic pelvic pain (CPP), with a clear neurologic examination and approval for SCS during multidisciplinary consultation. All participants received a Boston device with two 16-contact Infinion CX leads placed between T8 and T12, with a 14-day trial period before permanent implantation. Inclusion stopped when seven participants experienced ≥ 50% symptom improvement at 6-month follow-up. Pain symptom reduction (in NRS) was used as the primary outcome. Secondary outcomes included change in QoL (NRS; Endometriosis Health Profile-30 [EHP-30]), Short Fatigue Questionnaire, Pain Catastrophizing Scale, and analgesic use. Data were collected through questionnaires and during examination visits. Nine participants underwent SCS, and after a successful trial period, all had a permanent implantation. Improvement in general and worst pain, and of dysmenorrhea, CPP, dysuria, and dyschezia was observed when comparing baseline with different follow-up moments. Improvement was found in self-reported QoL scores and in all but one of the EHP-30 core domains. All participants but one were able to reduce their analgesics. One participant underwent device explantation owing to lack of effect at 12-month follow-up. SCS reduced intractable, endometriosis-related visceral pain and improved QoL. Because no sample size calculation could be performed, the results should be interpreted with caution. We emphasize the need to further study the application of SCS for endometriosis by performing randomized studies, which also includes a cost-analysis. The Clinicaltrials.gov registration number for the study is NCT05558540.